AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of “Moderate Buy” from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $50.30.

ANAB has been the topic of several recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a research report on Wednesday. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of AnaptysBio in a research report on Friday, May 10th. Finally, Truist Financial lifted their target price on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday.

AnaptysBio Stock Down 6.3 %

Shares of ANAB opened at $32.45 on Friday. The stock has a market cap of $886.50 million, a P/E ratio of -5.29 and a beta of -0.25. The business’s 50 day moving average price is $29.34 and its 200-day moving average price is $25.55. AnaptysBio has a 52 week low of $13.36 and a 52 week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 161.40% and a negative net margin of 711.17%. The company had revenue of $10.97 million during the quarter, compared to the consensus estimate of $25.85 million. On average, equities analysts anticipate that AnaptysBio will post -6.32 EPS for the current year.

Insider Buying and Selling

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. Following the completion of the sale, the insider now directly owns 11,618 shares of the company’s stock, valued at $406,630. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the completion of the sale, the insider now owns 11,618 shares of the company’s stock, valued at $406,630. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hollings Renton sold 1,950 shares of the company’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $23.16, for a total value of $45,162.00. Following the completion of the sale, the director now owns 1,950 shares of the company’s stock, valued at approximately $45,162. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,900 shares of company stock valued at $484,824. 33.70% of the stock is owned by insiders.

Hedge Funds Weigh In On AnaptysBio

Several large investors have recently added to or reduced their stakes in ANAB. Frazier Life Sciences Management L.P. raised its position in shares of AnaptysBio by 140.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after purchasing an additional 1,265,891 shares during the period. First Light Asset Management LLC increased its stake in AnaptysBio by 56.4% in the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after buying an additional 446,372 shares in the last quarter. Great Point Partners LLC increased its stake in AnaptysBio by 9.2% in the 4th quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock worth $20,927,000 after buying an additional 82,648 shares in the last quarter. Franklin Resources Inc. raised its holdings in AnaptysBio by 22.7% during the fourth quarter. Franklin Resources Inc. now owns 405,115 shares of the biotechnology company’s stock valued at $8,678,000 after acquiring an additional 75,025 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in shares of AnaptysBio by 38.2% in the second quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company’s stock valued at $7,684,000 after acquiring an additional 84,795 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.